Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Acquired by New York State Common Retirement Fund

New York State Common Retirement Fund grew its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 163.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 64,906 shares of the company's stock after purchasing an additional 40,300 shares during the quarter. New York State Common Retirement Fund's holdings in Vir Biotechnology were worth $476,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. KBC Group NV grew its position in shares of Vir Biotechnology by 136.5% during the fourth quarter. KBC Group NV now owns 8,970 shares of the company's stock worth $66,000 after buying an additional 5,177 shares in the last quarter. CIBC Asset Management Inc purchased a new stake in shares of Vir Biotechnology in the 4th quarter valued at approximately $74,000. Captrust Financial Advisors acquired a new stake in shares of Vir Biotechnology in the 3rd quarter valued at $118,000. Quarry LP raised its holdings in shares of Vir Biotechnology by 901.8% in the 3rd quarter. Quarry LP now owns 17,000 shares of the company's stock valued at $127,000 after purchasing an additional 15,303 shares in the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of Vir Biotechnology during the 3rd quarter worth $138,000. Hedge funds and other institutional investors own 65.32% of the company's stock.

Vir Biotechnology Price Performance

Shares of NASDAQ:VIR traded down $0.11 on Friday, reaching $7.96. The company's stock had a trading volume of 839,150 shares, compared to its average volume of 2,351,715. The stock's 50-day moving average is $9.51 and its two-hundred day moving average is $8.48. Vir Biotechnology, Inc. has a 52-week low of $6.56 and a 52-week high of $14.45. The stock has a market capitalization of $1.09 billion, a P/E ratio of -2.03 and a beta of 1.17.

Remove Ads

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The firm had revenue of $12.37 million during the quarter, compared to the consensus estimate of $8.14 million. Equities analysts forecast that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

VIR has been the topic of a number of analyst reports. Needham & Company LLC restated a "buy" rating and issued a $19.00 price target on shares of Vir Biotechnology in a research note on Thursday, February 27th. JPMorgan Chase & Co. boosted their price target on shares of Vir Biotechnology from $10.00 to $14.00 and gave the company a "neutral" rating in a research report on Thursday, January 9th. HC Wainwright reissued a "buy" rating and issued a $110.00 price target on shares of Vir Biotechnology in a research report on Friday, February 28th. Leerink Partners boosted their target price on Vir Biotechnology from $18.00 to $20.00 and gave the company an "outperform" rating in a report on Monday, January 13th. Finally, Morgan Stanley raised Vir Biotechnology from an "equal weight" rating to an "overweight" rating and boosted their target price for the company from $10.00 to $20.00 in a report on Thursday, January 9th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $35.67.

Insiders Place Their Bets

In other news, Director George A. Scangos sold 10,964 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total transaction of $107,556.84. Following the completion of the transaction, the director now directly owns 708,295 shares of the company's stock, valued at approximately $6,948,373.95. This represents a 1.52 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Vicki L. Sato sold 10,960 shares of the stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the transaction, the director now directly owns 1,312,391 shares of the company's stock, valued at approximately $16,431,135.32. This trade represents a 0.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 30,859 shares of company stock worth $326,458. 15.60% of the stock is owned by insiders.

Vir Biotechnology Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).